0270-9139/89/1006-1037$02.00/0
HEPATOLOGY
Copyright © 1989 by The American Association for the Study of Liver Diseases
Vol. 10, No. 6, pp. 1037–1044, 1989
*Printed in U.S.A.*

# Subject Index to Volume 10

Acetaldehyde
  adduct, 37 kDa liver protein, chronic alcohol ingestion, 807
  nonalcoholic liver injury, threonine or ethanol administration, 933
Acetaminophen, enhanced toxicity, bilirubin gluronyl transferase deficiency, 163
Adenine arabinoside 5′-monophosphate, randomized controlled trial, chronic active hepatitis B, 328
Alanine aminotransferase, elimination from plasma, fractional catabolic rate constants, 833
Albumin, hemopexin and liver fatty acid-binding protein, interaction with protoporphyrin, 995
Alcohol
  ethanol administration, experimental methods, 501
  ethanol-inducible P450IIE1, intralobular distribution, rat and human liver, 437
  -induced hepatomegaly, rat liver microcirculation, 941
  infusion to measure hepatic blood flow, HEPATOLOGY *Elsewhere*, 1021
Alcoholic liver disease
  animal models, HEPATOLOGY *Elsewhere* Correspondence, 898, 899
  splanchnic hemodynamics, propylthiouracil and methimazole effects, 273
Alginate-polylysine membranes, microencapsulation system, development and evaluation, primary rat hepatocytes, 855
Amineptine, drug hepatotoxicity, genetic predisposition, 168
Amino acids, branched-chain, management, hepatic encephalopathy, 228
γ-Aminobutyric acid, benzodiazepine receptors, autoradiography, acute hepatic encephalopathy, 143
5-Aminolevulinate, mechanism of iron potentiation, hepatic uroporphyria, 354
Aminopyrine, breath test, interference from nitrous oxide, 526, 527
Aminotransferases, elevated, liver disease, asymptomatic patients, 524
Amiodarone, hepatotoxicity, HEPATOLOGY *Elsewhere*, 116
Ammonia
  blood, orally administered L-carnitine, portacaval-shunted rats, 822
  liberation after bleeding in digestive tract, isoleucine absence in hemoglobin, 315
Ammonium acetate, simple animal model of hyperammonemia, 311
Anastomosis, portacaval, HEPATOLOGY *Elsewhere*, 1026
Androgen
  -estrogen receptor status, sex of donor, orthotopic liver transplantation, 861
  tumoral growth and plasma sex steroid levels, D-tryptophan-6-luteinizing hormone-releasing hormone, cirrhosis and hepatocellular carcinoma, 346
Anemia, aplastic, liver transplantation, HEPATOLOGY *Elsewhere*, 520
Angiography, undetected small hepatocellular carcinoma, follow-up and treatment, 1003
Antibodies, hepatitis B virus polymerase antigen, HBV-infected patients, 332
Antidepressants, amineptine, drug hepatotoxicity, genetic predisposition, 168
Antimitochondrial antibodies
  cross-reactivity, primary biliary cirrhosis autoantibodies, 370
  molecular aspects of M2 autoantigens, primary biliary cirrhosis, 247
  primary biliary cirrhosis, cross-reactive epitopes, protein X, 127
Antipyretic drugs, hepatitis during measles, young adults, 203
Antipyrine, clearance in chronic active hepatitis B, 192
$\alpha_1$-Antitrypsin, deficiency, sex and breastfeeding, liver disease, 122
Artery, hepatic blood flow, β-blockade with propranolol, cirrhosis, 269
Ascites
  endotoxin-induced formation, partial mediation, platelet-activating factor, 788
  pathogenesis, endogenous opioid peptides, HEPATOLOGY *Elsewhere*, 896
  portal hypertension and, acute hepatitis, 482
  refractory, portocardiorenal axis, HEPATOLOGY *Elsewhere*, 114
Aspartate aminotransferase, elimination from plasma, fractional catabolic rate constants, 833
Assays
  antiviral, prolonged duck hepatitis B virus replication, rat epithelial cells, 186
  diagnosis of hepatitis delta virus infection, 1014
  hepatitis delta virus antigen in serum, chronic delta hepatitis, 907
  *in situ* hybridization, intrahepatic markers, hepatitis delta virus, 916
Atrial natriuretic factor
  augmentation of natriuretic response, cirrhosis, 897
  early cirrhosis, 148
  plasma concentration, liver cirrhosis, 263
  refractory ascites, portocardiorenal axis, HEPATOLOGY *Elsewhere*, 114
Autoantibodies
  IgG and IgM, frequency to M2 mitochondrial autoantigens, primary biliary cirrhosis, 403
  primary biliary cirrhosis, cross-reactivity, antimitochondrial antibodies, 370
  treatment of chronic type B hepatitis, α-interferon, 24
Autoantigens, M2, primary biliary cirrhosis, HEPATOLOGY *Elsewhere*, 389
Autoradiography, GABA-benzodiazepine receptors, animal model, acute hepatic encephalopathy, 143

Baroreflex, cardiopulmonary, nitroglycerin and splanchnic hemodynamics, cirrhosis, 93
Benzodiazepine, antagonist Ro 15-1788, pharmacokinetics, cirrhosis, 969
Bile
  cholesterol and pigment gallstones, differentiation, HEPATOLOGY *Elsewhere*, 518
  horseradish peroxidase transport into lumina, monensin effects, hepatocytes, 61
  inhibited secretion, protein kinase C agonists, perfused rat liver, 8
Bile acid
  inhibition, endotoxin-induced tumor necrosis factor release, monocytes, 454
  intraduodenal administration, biliary secretion, calcium and carbonate, 134
  metabolism, ursodeoxycholic acid effect, primary biliary cirrhosis, 414
  uptake by perfused rat liver, structure-activity relationship, 840
Bile duct
  diverticular lesion, chronic active hepatitis, 774
  human ontogeny, portal space ratio, 21

Biliary disease, neonatal, reovirus 3, HEPATOLOGY *Elsewhere*, 515
Bilirubin
  glucuronyl transferase deficiency, enhanced acetaminophen toxicity, 163
  maximal biliary output, administration of unconjugated bilirubin, bilirubin diglucuronide, 14
Blood, ammonia, orally administered L-carnitine, portacaval-shunted rats, 822
Blood flow
  decrease in portal pressure with propranolol, no change in collateral resistance, cirrhotic rats, 953
  hepatic, measurement with alcohol infusion, HEPATOLOGY *Elsewhere*, 1021
  hepatic artery, $\beta$-blockade with propranolol, cirrhosis, 269
  hepatic drug clearance, chronic liver disease, HEPATOLOGY *Elsewhere*, 892
  hepatic enzymic zonation, concept evaluation, liver acinus, 72
  increased galactose clearance, liver transplantation, 288
  splanchnic hemodynamics
    clonidine-induced portal pressure decrease, normal and cirrhotic rats, 477
    ethanol effect, portal hypertension in rats, 946
    propylthiouracil and methimazole effects, 273
Blood group-related antigens, biliary tree and hepatocytes, normal liver, hepatobiliary diseases, 174
Blood pressure, low, atrial natriuretic factor, early cirrhosis, 148
Bone, loss, controlled prednisolone trial, primary biliary cirrhosis, 420
Book Reviews, 120, 259, 395, 522, 900, 1028
Brain
  intermediate filament pathology, HEPATOLOGY *Elsewhere*, 514
  intracranial hypertension, thiopental infusion, fulminant hepatic failure, 306
Breastfeeding, sex and, liver disease influence, $\alpha_1$-antitrypsin deficiency, 122
Breath test, assessment of mitochondrial function, $\alpha$-ketoisocaproic acid, 829
Butyl cyanoacrylate, successful endoscopic obturation, gastric varices, 488

Caffeine, fasting plasma level, cirrhosis, 973
Calcium
  current status in hepatocellular injury, 375
  intraduodenal bile acid administration, biliary secretion, 134
Capillary, spiders and, HEPATOLOGY *Elsewhere*, 388
Carbohydrate, metabolism in hepatocellular carcinoma, glucose, HEPATOLOGY *Elsewhere*, 252
Carbonate, intraduodenal bile acid administration, biliary secretion, 134
Carbon tetrachloride, administration, cellular analysis, c-Ha-*ras* gene expression, 494
Carcinoma, hepatocellular
  angiographically undetected, follow-up and treatment, 1003
  carbohydrate metabolism, glucose, HEPATOLOGY *Elsewhere*, 252
  cirrhosis and, D-tryptophan-6-luteinizing hormone-releasing hormone, tumoral growth, 346
  five-year experience of lipiodolization, chemotherapy, 98
  iron-accumulative macroregenerative nodules, survey, cirrhotic liver, 851
  prevalence, relation to cirrhosis, Italy and Japan, 998
  unresectable, adoptive immunotherapy, LAK cells plus IL-2, 349
  woodchuck, woodchuck hepatitis virus DNA and RNA, 215
  woodchuck hepatitis virus interaction, hepatocyte plasma membrane, 44
Cardiovascular system, altered hemodynamic response to hemorrhage, hepatic denervation, 473
L-Carnitine, orally administered, blood ammonia, portacaval-shunted rats, 822
Catecholamines, fasting plasma caffeine level, cirrhosis, 973
Celiac disease, primary sclerosing cholangitis and, association, HEPATOLOGY *Elsewhere*, 1020
Cell culture, *in vitro* replication and expression, hepatitis B virus, chimpanzee hepatocytes, 921
Chemotherapy, five-year experience of lipiodolization, hepatocellular carcinoma, 98
Chenodeoxycholic acid, intraduodenal bile acid administration, biliary secretion, 134
Chloramphenicol acetyltransferase, heterologous viral promoters, tissue-specific activity, hepatocytes and Hep G2 cells, 781
Cholescintigraphy, $^{99m}$Tc-DISIDA and biliary manometry, sphincter of Oddi function, HEPATOLOGY *Elsewhere*, 895
Cholestasis, benign recurrent intrahepatic, 1027
Cirrhosis
  augmentation of natriuretic response, atrial natriuretic factor, HEPATOLOGY *Elsewhere*, 897
  clonidine-induced decrease, mechanisms, 477
  decrease in portal pressure with propranolol, no change in collateral resistance, 953
  dietary model, serum procollagen III peptide, hepatic hydroxyproline content, 801
  disseminated intravascular coagulation, 103
  early, atrial natriuretic factor, 148
  fasting plasma caffeine level, 973
  HBsAg-positive, isosorbide-5-mononitrate, hepatic hemodynamics, 283
  hepatic artery blood flow, $\beta$-blockade with propranolol, 269
  hepatocellular carcinoma and, D-tryptophan-6-luteinizing hormone-releasing hormone, tumoral growth, 346
  iron-accumulative macroregenerative nodules, survey, 851
  liver, plasma concentration, atrial natriuretic factor, 263
  low dose of nitroglycerin, failure to improve splanchnic hemodynamics, 93
  pharmacokinetics of Ro 15-1788, 969
  prevalence of hepatocellular carcinoma, Italy and Japan, 998
  primary biliary: *see* Primary biliary cirrhosis
  timing of postprandial hemodynamic events, 1027, 1027
Clonidine, -induced decrease in portal pressure, normal and cirrhotic rats, 477
Collagen
  deposition, $\gamma$-interferon treatment, murine schistosomiasis, 795
  value of serum procollagen III peptide, hepatic hydroxyproline content, model of dietary cirrhosis, 801
Collagenase, active and latent activity, reversal of hepatic fibrosis, schistosomiasis, 77
Complements, acute massive necrosis of liver, HEPATOLOGY *Elsewhere*, 117
Correspondence
  Akahane, Tsuda, and Mayumi: To the Editor, 398
  Bircher: To the Editor, 1027
  Czaja, Hay, and Rakela: Reply, 524
  D'Arienzo and Mazzacca: Reply, 262
  Gaiani, Bolondi, and Barbara: Reply, 1027
  Ghishan: Reply, 122
  Ginès and Arroyo: Reply, 263
  Hickman: Reply, 527
  Koblin: To the Editor, 526
  Konikoff, Pecht, Theodor, and Shoenfeld: To the Editor, 525
  Labrune, Odièvre, and Alagille: To the Editor, 122
  Lee: To the Editor, 1027
  Liaw: To the Editor, 398
  Lindor: Reply, 526
  Lok: Reply, 399
  Nayak: To the Editor, 902
  Okuda: To the Editor, 903
  Orozco, Garcia-Tsao, and Takahashi: Reply, 903
  Sampliner: To the Editor, 524

Correspondence—*continued*
Tulassay, Tulassay and Rascher: To the Editor, 263
Urbain and Ham: To the Editor, 262
Cytosol
estrogen-androgen receptor status, sex of donor, orthotopic liver transplantation, 861
liver enzymes, elimination from plasma, fractional catabolic rate constants, 833

Dane particles, HBcAg expression, hepatitis B virus infection, no anti-HBc formation, 179
Daunomycin, galactose and *N*-(2-hydroxypropyl)methacrylamide, interaction, hepatoma cells, 207
Diet, ethanol administration, experimental methods, 501
Digestion, intracellular, liver, 877
Digestive tract, ammonia liberation after bleeding, isoleucine absence in hemoglobin, 315
Dihydrolipoamide acetyltransferase, antimitochondrial autoantibodies, primary biliary cirrhosis, cross-reactive epitopes, 127
Dimethyl sulfoxide, replication of duck hepatitis B virus, primary duck hepatocytes, host cell differentiation, 459
Dipyrone, antipyretic drugs, hepatitis during measles, young adults, 203
DNA
κB sequence-specific binding protein, tumor necrosis factor-α, hepatoblastoma cells, 1008
woodchuck hepatitis virus, hepatocellular carcinoma of woodchucks, 215
DNA polymerase, postexposure immunoprophylaxis, HBV infection, 324, 398
Drug clearance, hepatic, chronic liver disease, HEPATOLOGY *Elsewhere*, 892

Editorial
Christensen: prognostication in primary biliary cirrhosis, 111
Combes: prednisolone for primary biliary cirrhosis, 511
Di Bisceglie: diagnosis of hepatitis delta virus infection, 1014
Dienstag: passive-active immunization for hepatitis B, 385
James, Yeaman, and Bassendine: molecular aspects of M2 autoantigens, 247
Malter and Gerber: regulation of hepatocyte gene expression, 1017
Nolan: intestinal endotoxins as mediators of hepatic injury, 887
Eicosanoid, synthesis, enzymes, portacaval shunting, 154
Encephalopathy
acute hepatic, GABA-benzodiazepine receptors, autoradiography, 143
hepatic, management, branched-chain amino acids, 228
Endoscopy, successful obturation, gastric varices, butyl cyanoacrylate, 488
Endothelial cells, reperfusion injury, cold ischemic storage, rat livers, 292
Endotoxin
-induced ascites formation, partial mediation, platelet-activating factor, 788
-induced release of tumor necrosis factor, inhibition by bile acids, monocytes, 454
intestinal, mediation of hepatic injury, 887
Enzymes
bioavailability, eicosanoid synthesis, portacaval shunting, 154
cytosolic, elimination from plasma, fractional catabolic rate constants, 833
Epithelial cells, rat, prolonged duck hepatitis B virus replication, antiviral testing, 186
Estrogen, -androgen receptor status, sex of donor, orthotopic liver transplantation, 861
Ethanol
administration, experimental methods, 501
alcoholic liver disease, animal models, HEPATOLOGY *Elsewhere*
Correspondence, 898, 899
chronic feeding in rat, lipid peroxidation, antioxidant defense systems, 815
high levels of acetaldehyde, nonalcoholic liver injury, 933
-inducible P450IIE1, intralobular distribution, rat and human liver, 437
splanchnic hemodynamics, portal hypertension, rats, 946

Fatty acid-binding protein, hemopexin and albumin, interaction with protoporphyrin, 995
α-Fetoprotein
angiographically undetected small hepatocellular carcinoma, follow-up and treatment, 1003
chronic HBV infection, 398, 399
Fibrin, disseminated intravascular coagulation, cirrhosis, 103
Fibrosis
hepatic, collagenase activity, schistosomiasis, 77
procollagen types I/III/IV mRNA, *in situ* hybridization, 84
France, male HBsAg-positive homosexuals, hepatitis delta virus infection, 342

Galactose
increased clearance after liver transplantation, 288
interaction of *N*-(2-hydroxypropyl)methacrylamide copolymers, daunomycin, hepatoma cells, 207
Gallstone
cholesterol and pigment, differentiation, HEPATOLOGY *Elsewhere*, 518
pancreatitis, signs for intervention, HEPATOLOGY *Elsewhere*, 1022
Gastrointestinal erosions, endotoxin-induced ascites formation, partial mediation, platelet-activating factor, 788
Gastropathy, congestive, portal hypertension, HEPATOLOGY *Elsewhere*, 257
Gene, hepatocyte, regulation of expression, 1017
Glucose, carbohydrate metabolism, HEPATOLOGY *Elsewhere*, 252
Glucuronyl transferase, deficiency, enhanced acetaminophen toxicity, 163

HBcAg, surface of circulating Dane particles, hepatitis B virus infection, no anti-HBc formation, 179
HBeAg, serial antipyrine clearance, chronic active hepatitis B disease, 192
HBsAg
lack of immune potentiation, hepatitis B vaccine, 36
-positive cirrhosis, hepatic hemodynamics, isosorbide-5-mononitrate, 283
-positive homosexuals, hepatitis delta virus infection, French males, 342
woodchuck hepatitis virus interaction, hepatocyte plasma membrane, 44
Heart, hepatic blood flow, β-blockade with propranolol, cirrhosis, 269
Heme oxygenase, human tissue, sensitivity to synthetic metalloporphyrin, 365
Hemodialysis, postexposure immunoprophylaxis, HBV infection, 324, 398
Hemodynamics
altered response to hemorrhage, hepatic denervation, 473
hepatic, isosorbide-5-mononitrate, HBsAg-positive cirrhosis, 283
increased galactose clearance, liver transplantation, 288
metabolic responses to leukotriene $C_4$, rat liver, 300
portal hypertension and ascites, acute hepatitis, 482
postprandial events, timing, cirrhosis, 1027, 1027
splanchnic
ethanol effects, portal hypertension in rats, 946
nitroglycerin, cirrhosis, 93
propylthiouracil and methimazole effects, 273
Hemoglobin, absence of isoleucine, ammonia liberation, bleeding in digestive tract, 315

Hemopexin, albumin and liver fatty acid-binding protein, interaction with protoporphyrin, 995
Hemorrhage
active variceal, tamponade *vs.* sclerotherapy, HEPATOLOGY *Elsewhere*, 393
acute, esophageal varices, somatostatin multicenter trial, 958
altered hemodynamic response, hepatic denervation, 473
variceal, transdermal nitroglycerin, vasopressin infusion, 962
Hepatitis
acute, portal hypertension, ascites, 482
acute viral
chronic carrier of HBV, HEPATOLOGY *Elsewhere*, 252
soluble interleukin 2 receptor, 928
chronic active
diverticular bile duct lesion, 774
elevated aminotransferases, asymptomatic patients, 524
extrahepatic malignancy, long-term immunosuppressive therapy, 39
drug hepatotoxicity, amineptine, genetic predisposition, 168
during measles in young adults, role, antipyretic drugs, 203
fulminant viral, aplastic anemia after transplantation, HEPATOLOGY *Elsewhere*, 520
Hepatitis B
chronic
anti-HBe-positive, natural course and response, interferon, 198
interferon effects, 2′,5′-oligoadenylate synthetase, 29
α-interferon treatment, autoantibodies, 24
trial of human lymphoblastoid interferon, Italy, 336
chronic active
randomized controlled trial, adenine arabinoside 5′-monophosphate, 328
serial antipyrine clearance, 192
heat-inactivated vaccine, lack of immune potentiation, HBsAg complexed to antibody, 36
Hepatitis B virus
accidental infection in hemodialysis staff members, postexposure prophylaxis, hepatitis B immune globulin and vaccine, 324, 398
antibodies against polymerase antigen, HBV-infected patients, 332
chronic, response to α-interferon therapy, 761
chronic carriers, acute viral hepatitis, HEPATOLOGY *Elsewhere*, 252
duck
prolonged replication, antiviral testing, 186
replication in primary duck hepatocytes, host cell differentiation, 459
α-fetoprotein in chronic infection, 398, 399
HBcAg expression on Dane particles, no evidence of anti-HBc formation, 179
*in vitro* replication and expression, primary chimpanzee hepatocytes, 921
passive-active immunization, 385
tissue-specific activity, heterologous viral promoters, rat hepatocytes, 781
Hepatitis delta virus
chronic active, compostion, mononuclear cell infiltrates, 911
cytoplasmic antigen in hepatocytes, relationship to interferon, 764
detection of antigen by immunoblot, markers of delta viral replication, 907
diagnosis of infection, 1014
infection in French male HBsAg-positive homosexuals, 342
intrahepatic markers, *in situ* hybridization, 916
Hepatitis D virus, RNA in sera and chronic HDV, correlation, IgM anti-hepatitis D virus, 34
Hepatitis non-A/non-B
chronic active hepatitis, diverticular bile duct lesion, 774
cytoplasmic antigen in hepatocytes, relationship to interferon, 764
enterically transmitted, transmission studies, 466
Hepatitis virus
woodchuck
DNA and RNA, hepatocellular carcinoma of woodchucks, 215
interaction, hepatocyte plasma membrane, 44
Hepatobiliary diseases, blood group-related antigens, biliary tree, hepatocytes, 174
Hepatoblastoma cells, κB sequence-specific DNA-binding protein, tumor necrosis factor-α, 1008
Hepatocytes
binding and uptake, low-density lipoproteins, 56
blood group-related antigens, biliary tree, normal liver and hepatobiliary diseases, 174
chimpanzee, replication and expression, hepatitis B virus, 921
cytoplasmic antigen, non-A/non-B hepatitis virus or hepatitis delta virus, interferon, 764
electronic cell sizing, sodium:proton exchange, 986
horseradish peroxidase transport into lumina, monensin effects, 61
plasma membrane, interaction, woodchuck hepatitis virus, 44
primary duck, replication, duck hepatitis B virus, 459
primary rat, system of microencapsulation, development and evaluation, 855
regulation of gene expression, 1017
tissue-specific activity, heterologous viral promoters, 781
HEPATOLOGY *Elsewhere*
Amatruda and Salhanick: insulin and steatonecrosis, 1024
Bar-Meir and Chamovitz: sphincter of Oddi function, 895
Conn: portacaval anastomosis, 1026
Denk, Zatloukal, and Preisegger: ubiquitin-intermediate filament pathology, 514
Elliott: gallstone pancreatitis, 1022
Epstein: presymptomatic Wilson's disease, 892
Gerbes: augmentation of natriuretic response to atrial natriuretic factor in cirrhosis, 897
Henriksen: opioid peptides in ascites pathogenesis, 896
Hosking: congestive gastropathy in portal hypertension, 257
Jüngst: cholesterol and pigment gallstones, 518
Knox and Kaplan: myeloproliferative disorders in portal vein thrombosis, 392
Lee: alcohol infusion to measure hepatic blood flow, 1021
Lok: acute viral hepatitis in chronic carriers, 252
Mackay, Rowley, and Armstrong: M2 autoantigens in primary biliary cirrhosis, 389
Marchesini and Bianchi: carbohydrate metabolism in hepatocellular carcinoma, 253
Morecki and Glaser: reovirus 3 and neonatal biliary disease, 515
Morgan and Smallwood: hepatic drug clearance in chronic liver disease, 893
Okuda: acute massive necrosis by antibody/complement, 118
Rabeneck: treatment of bleeding varices, 517
Rigas: aminodarone hepatotoxicity, 116
Schrumpf: primary sclerosing cholangitis and celiac disease, 1020
Sherlock: spiders and capillaries, 388
Taylor: portal vein patency, 117
Terés: balloon tamponade *vs.* endoscopic sclerotherapy, 393
Tredger and Williams: drug-binding proteins after transplantation, 390
Wanless: coexistent pulmonary and portal hypertension, 255
Witte and Witte: portocardiorenal axis and refractory ascites, 114
Zeldis: aplastic anemia after liver transplantation, 520
HEPATOLOGY *Elsewhere* Correspondence
Elias: impaired sulfoxidation in primary biliary cirrhosis, 1027
French and Tsukamoto: animal models for alcoholic liver disease, 898
Mezey: animal models for alcoholic liver disease, 899
Hepatoma cells, galactose and *N*-(2-hydroxypropyl)methacrylamide, interaction, daunomycin, 207
Hepatomegaly, alcohol-induced, rat liver microcirculation, 941

Hepatotoxicity
amiodarone, HEPATOLOGY *Elsewhere*, 116
drug, genetic predisposition, amineptine, 168
Hep G2 cells, tissue-specific activity, heterologous viral promoters, 781
Homosexuals
French male HBsAg-positive, hepatitis delta virus infection, 342
randomized controlled trial, adenine arabinoside 5′-monophosphate, chronic active hepatitis B, 328
Horseradish peroxidase, monensin effects, intracellular lumina, hepatocytes, 61
Hydroxyproline, hepatic content, serum procollagen III peptide, model of dietary cirrosis, 801
*N*-(2-Hydroxypropyl)methacrylamide, copolymers, galactose interaction, hepatoma cells, 207
Hyperammonemia, simple animal model, 311
Hyperbilirubinemia, sensitivity of human tissue heme oxygenase, synthetic metalloporphyrin, 365
Hyperplasia, nodular regenerative, pulmonary and portal hypertension, HEPATOLOGY *Elsewhere*, 255
Hypertension
intracranial, thiopental infusion, fulminant hepatic failure, 306
portal, isosorbide-5-mononitrate, HBsAg-positive cirrhosis, 283
pulmonary and portal, coexistence, HEPATOLOGY *Elsewhere*, 252

Immunization, passive-active, hepatitis B, 385
Immunoglobulin, hepatitis B, lack of immune potentiation, hepatitis B vaccine, 36
Immunoglobulin G
frequency of autoantibodies, M2 mitochondrial autoantigens, primary biliary cirrhosis, 403
37 kDa liver protein-acetaldehyde adduct, chronic alcohol ingestion, 807
Immunoglobulin M
anti-hepatitis D virus, HDV virus RNA in sera, chronic HDV, 34
frequency of autoantibodies, M2 mitochondrial autoantigens, primary biliary cirrhosis, 403
Immunoregulation, defective, primary biliary cirrhosis, 408
Immunosuppressive therapy, long-term, extrahepatic malignancy, chronic active hepatitis, 39
Immunotherapy
adoptive, LAK cells plus IL-2, unresectable hepatocellular carcinoma, 349
LAK cell activity, primary and metastatic malignant liver tumors, 221
Infants, preterm, human ontogeny, bile duct to portal space ratio, 21
Insulin, steatonecrosis and, HEPATOLOGY *Elsewhere*, 1024
Interferon
cytoplasmic antigen in hepatocytes, non-A/non-B hepatitis virus or hepatitis delta virus, 764
human lymphoblastoid, controlled trial, chronic hepatitis B in Italy, 336
induction of 2′,5′-oligoadenylate synthetase, chronic hepatitis B, 29
natural course and response, chronic anti-HBe-positive hepatitis B, 198
α-Interferon
response to therapy, predictive factors, chronic hepatitis B virus, 761
treatment of chronic type B hepatitis, induction, autoantibodies, 24
γ-Interferon, inhibition of collagen deposition, murine schistosomiasis, 795
Interleukin 2, adoptive immunotherapy with LAK cells, unresectable hepatocellular carcinoma, 349
Intermediate filament, pathology of brain and liver, HEPATOLOGY *Elsewhere*, 514
Intestine
bleeding in digestive tract, ammonia liberation, isoleucine absence in hemoglobin, 315
endotoxins, mediation of hepatic injury, 887
Iron
-accumulative macroregenerative nodules, survey, cirrhotic livers, 851
mechanism of potentiation, hepatic uroporphyria, 354
Isoleucine, absence in hemoglobin, ammonia liberation, bleeding in digestive tract, 315
Isosorbide-5-mononitrate, lack of effects, hepatic hemodynamics, HBsAg-positive cirrhosis, 283
Italy
controlled trial of human lymphoblastoid interferon, chronic hepatitis B, 336
prevalence of hepatocellular carcinoma, relation to cirrhosis, 998

Japan, prevalence of hepatocellular carcinoma, relation to cirrhosis, 998
Jaundice, endotoxin-induced release of tumor necrosis factor, inhibition by bile acids, monocytes, 454

α-Ketoisocaproic acid, assessment of mitochondrial function, breath test, 829

Lactate dehydrogenase, elimination from plasma, fractional catabolic rate constants, 833
LAK cells
adoptive immunotherapy, unresectable hepatocellular carcinoma, 349
primary and metastatic malignant liver tumors, 221
Leukotriene $C_4$, hemodynamic and metabolic responses, rat liver, 300
Lipid peroxidation, antioxidant defense systems, chronic ethanol feeding, rat liver, 815
Lipids, ethanol administration, experimental methods, 501
Lipiodolization, five-year experience, chemotherapy, hepatocellular carcinoma, 98
Lipoproteins, low-density, binding and uptake, hepatocytes, 56
Liver
acute massive necrosis, antibody/complement, HEPATOLOGY *Elsewhere*, 117
$CCl_4$ administration, cellular analysis, c-Ha-*ras* gene expression, 494
chronic disease
hepatic drug clearance, HEPATOLOGY *Elsewhere*, 892
management of children, reduced-size orthotopic liver transplantation, 867
soluble interleukin 2 receptor, 928
cold ischemic storage, reperfusion injury, endothelial cells, 292
disease
elevated aminotransferases, asymptomatic patients, 524
sex and breastfeeding, $\alpha_1$-antitrypsin deficiency, 122
tumor necrosis factor α production, peripheral blood mononuclear cells, 769
disseminated intravascular coagulation, cirrhosis, 103
dysfunction, Ro 15-1788 pharmacokinetics, cirrhosis, 969
enzyme bioavailability, eicosanoid synthesis, portacaval shunting, 154
fulminant hepatic failure, thiopental infusion, intracranial hypertension, 306
hemodynamic and metabolic responses, leukotriene $C_4$, 300
hepatic denervation, altered hemodynamic response, hemorrhage, 473
hepatic enzymic zonation, concept evaluation, liver acinus, 72
hepatocellular injury, current status of calcium, 375
histology abnormalities, morbidly obese, 873
inhibition of bile secretion, protein kinase C agonists, 8
injury
mediation by intestinal endotoxins, 887
nonalcoholic, high acetaldehyde levels, 933
intermediate filament pathology, HEPATOLOGY *Elsewhere*, 514

Liver—*continued*
intracellular digestion, 877
microcirculation in rat, alcohol-induced hepatomegaly, 941
nonparenchymal and parenchymal cells, catabolism, extracellular purines, 66
normal, blood group-related antigens, biliary tree and hepatocytes, 174
perfused, bile acid uptake, structure-activity relationship, 840
primary and metastatic malignant tumors, LAK cell activity, 221
procollagen types I/III/IV mRNA, *in situ* hybridization, 84
rat and human, intralobular distribution, ethanol-inducible P450IIE1, 437
splanchnic hemodynamics, propylthiouracil and methimazole effects, 273
transplantation: *see* Transplantation
transplantation rejection, 978
uroporphyria, mechanism, iron potentiation, 354
Lumina, intracellular, monensin effects, horseradish peroxidase transport, 61
Lymphocytes, subsets and function in time frame, primary biliary cirrhosis, 525, 526
Lysosomes, liver and intracellular digestion, 877

Macroregenerative nodules, iron-accumulative, survey, cirrhotic liver, 851
Malignancy, extrahepatic, long-term immunosuppressive therapy, chronic active hepatitis, 39
Manometry, endoscopic biliary, $^{99m}$Tc-DISIDA and sphincter of Oddi function, HEPATOLOGY *Elsewhere*, 895
Mayo model, primary biliary cirrhosis, extramural cross-validation, 846
Measles, hepatitis and, antipyretic drugs, young adults, 203
Metalloporphyrin, synthetic, sensitivity, human tissue heme oxygenase, 365
Metastasis, liver tumors, LAK cell activity, 221
Methimazole, propylthiouracil and, splanchnic hemodynamics, 273
Methionine enkephalin, endogenous opioid peptides, pathogenesis of ascites, HEPATOLOGY *Elsewhere*, 896
Microcirculation, rat liver, alcohol-induced hepatomegaly, 941
Microencapsulation, system development and evaluation, primary rat hepatocytes, 855
Mitochondria
assessment of function, breath test, $\alpha$-ketoisocaproic acid, 829
M2 autoantigens, frequency of IgG and IgM autoantibodies, primary biliary cirrhosis, 403
Monensin, transport of horseradish peroxidase, intracellular lumina, hepatocytes, 61
Monocytes, endotoxin-induced release of tumor necrosis factor, inhibition by bile acids, 454
Mononuclear cells
composition of infiltrates, chronic active delta hepatitis, 911
peripheral blood, tumor necrosis factor $\alpha$ production, chronic liver disease, 769
Myeloproliferative disorders, portal vein thrombosis in adults, HEPATOLOGY *Elsewhere*, 390

$Na^+,K^+$-ATPase, taurocholate transport, basolateral plasma membrane vesicles, 447
Neonate, biliary disease, reovirus 3, HEPATOLOGY *Elsewhere*, 515
Nerve, hepatic denervation, altered hemodynamic response, hemorrhage, 473
Nevi, spider, capillaries and, HEPATOLOGY *Elsewhere*, 388
Nitroglycerin
failure to improve splanchnic hemodynamics, cirrhosis, 93
transdermal, association to vasopressin infusion, variceal hemorrhage, 962
Nitrous oxide, interference with aminopyrine breath test, 526, 527
Norepinephrine, fasting plasma caffeine level, cirrhosis, 973
Notices, 123, 265, 400, 528, 904, 1034

Obesity, morbid, liver histology abnormalities, 873
2′,5′-Oligoadenylate synthetase, interferon effects, chronic hepatitis B, 29
Opioid peptides, endogenous, pathogenesis of ascites, HEPATOLOGY *Elsewhere*, 896
2-Oxo acid dehydrogenase, molecular aspects of M2 autoantigens, primary biliary cirrhosis, 247
Oxygen, antioxidant defense systems, lipid peroxidation, chronic ethanol feeding, 815

Pancreatitis, gallstone, signs for intervention, HEPATOLOGY *Elsewhere*, 1022
Paracetamol, antipyretic drugs, hepatitis during measles, young adults, 203
pH, monitoring of sodium:proton exchange, electronic cell sizing, hepatocytes, 986
P450IIE1, ethanol-inducible, intralobular distribution, rat and human liver, 437
Plasma
caffeine level in cirrhotic patients, catecholamines, renin activity, 973
concentration of atrial natriuretic factor, liver cirrhosis, 263
elimination of cytosolic liver enzymes, fractional catabolic rate constants, 833
Plasma membrane
basolateral vesicles, taurocholate transport, 447
hepatocellular injury, current status of calcium, 375
hepatocyte, interaction, woodchuck hepatitis virus, 44
Platelet-activating factor, partial mediation, endotoxin-induced ascites formation, 788
Portal hypertension
ascites and, acute hepatitis, 482
congestive gastropathy, HEPATOLOGY *Elsewhere*, 257
idiopathic, thrombosis, protein C deficiency, 902, 903
pulmonary hypertension and, coexistence, HEPATOLOGY *Elsewhere*, 252
splanchnic hemodynamics, effect of ethanol, 946
Portal pressure
clonidine-induced decrease, normal and cirrhotic rats, 477
decrease with propranolol, no change in collateral resistance, cirrhotic rats, 953
Portal vein
patency, diagnostic comparative studies, HEPATOLOGY *Elsewhere*, 117
thrombosis, myeloproliferative disorders, HEPATOLOGY *Elsewhere*, 390
Potassium channel, monitoring of sodium:proton exchange, electronic cell sizing, hepatocytes, 986
Prednisolone
controlled trial, primary biliary cirrhosis, 420
primary biliary cirrhosis, 511
Primary biliary cirrhosis
antimitochondrial autoantibodies, cross-reactive epitopes, protein X, 127
bile acid metabolism, effect, ursodeoxycholic acid, 414
controlled trial of prednisolone, 420
cross-reactivity of autoantibodies, antimitochondrial antibodies, 370
defective immunoregulation, 408
frequency of IgG and IgM autoantibodies, M2 mitochondrial autoantigens, 403
impaired sulfoxidation, HEPATOLOGY *Elsewhere* Correspondence, 1027
lymphocyte subsets and function, time frame, 525, 526
M2 autoantigens, HEPATOLOGY *Elsewhere*, 389
Mayo, extramural cross-validation, 846

Primary biliary cirrhosis—*continued*
molecular aspects of M2 autoantigens, 247
prednisolone, 511
prognosis, model for decision making, 1
prognostication, 111
Primary sclerosing cholangitis
celiac disease and, association, HEPATOLOGY *Elsewhere*, 1020
natural history, prognostic factors, survival analysis, 430
Procollagen, types I/III/IV mRNA, normal and fibrotic liver, 84
Procollagen III peptide, serum, hepatic hydroxyproline content, model of dietary cirrhosis, 801
Propranolol
decrease in portal pressure, no change in collateral resistance, cirrhotic rats, 953
treatment comparisons, bleeding varices, HEPATOLOGY *Elsewhere*, 517
Propylthiouracil, methimazole and, splanchnic hemodynamics, 273
Protein
absence of isoleucine in hemoglobin, ammonia liberation, bleeding in digestive tract, 315
drug-binding, liver transplantation, HEPATOLOGY *Elsewhere*, 390
ethanol administration, experimental methods, 501
37 kDa, acetaldehyde adduct, chronic alcohol ingestion, 807
liver and intracellular digestion, 877
Protein C, deficiency, idiopathic portal hypertension, thrombosis, 902, 903
Protein kinase C, agonists, bile secretion inhibition, perfused rat liver, 8
Protein X
cross-reactive epitopes, antimitochondrial autoantibodies, primary biliary cirrhosis, 127
molecular aspects of M2 autoantigens, primary biliary cirrhosis, 247
Proteolysis, liver and intracellular digestion, 877
Proto-oncogenes, c-Ha-*ras*, cellular analysis, $CCl_4$ administration, 494
Protoporphyrin, interactions, hemopexin, albumin and liver fatty acid-binding protein, 995
Purines, extracellular, catabolism, nonparenchymal and parenchymal liver cells, 66
Pyruvate dehydrogenase, antimitochondrial autoantibodies, primary biliary cirrhosis, cross-reactive epitopes, 127

Receptors
estrogen-androgen status, sex of donor, orthotopic liver transplantation, 861
GABA-benzodiazepine, autoradiography, acute hepatic encephalopathy, 143
interleukin 2, solubility, acute viral hepatitis and chronic liver disease, 928
Renin, fasting plasma caffeine level, cirrhosis, 973
Reovirus 3, neonatal biliary disease, HEPATOLOGY *Elsewhere*, 515
RNA
diagnosis of hepatitis delta virus infection, 1014
IgM anti-hepatitis D virus, HDV in sera, chronic HDV, 34
*in situ* hybridization, intrahepatic markers, hepatitis delta virus, 916
woodchuck hepatitis virus, hepatocellular carcinoma of woodchucks, 215
RNA, messenger, procollagen types I/III/IV, normal and fibrotic liver, 84
Ro 15-1788, benzodiazepine antagonist, pharmacokinetics, cirrhosis, 969

Schistosomiasis
active and latent collagenase activity, reversal, hepatic fibrosis, 77
murine, inhibition of collagen deposition, $\gamma$-interferon, 795
Scintigraphy, thallium, portal pressure and portal perfusion, 262
Sclerotherapy
endoscopic, balloon tamponade, HEPATOLOGY *Elsewhere*, 393
injection, sucralfate for rebleeding prevention, esophageal varices, 279
treatment comparisons, bleeding varices, HEPATOLOGY *Elsewhere*, 517
Sex, breastfeeding and, liver disease influence, $\alpha_1$-antitrypsin deficiency, 122
Sex differences, estrogen-androgen receptor status, donor, orthotopic liver transplantation, 861
Shunt
hepatic blood flow, $\beta$-blockade with propranolol, cirrhosis, 269
portacaval
enzyme bioavailability, eicosanoid synthesis, 154
orally administered L-carnitine, blood ammonia, 822
portacaval anastomosis, HEPATOLOGY *Elsewhere*, 1026
Sodium, taurocholate transport, basolateral plasma membrane vesicles, 447
Sodium:proton exchange, hepatocyte monitoring, electronic cell sizing, 986
Somatostatin, multicenter trial, acute hemorrhage, esophageal varices, 958
Sphincter of Oddi, function, $^{99m}$Tc-DISIDA and biliary manometry, HEPATOLOGY *Elsewhere*, 895
Spiders, capillaries and, HEPATOLOGY *Elsewhere*, 388
Steatonecrosis, insulin and, HEPATOLOGY *Elsewhere*, 1024
Storage, cold ischemic, reperfusion injury to endothelial cells, rat liver, 292
Sucralfate, prevention of early rebleeding, injection sclerotherapy, esophageal varices, 279
Sulfoxidation, impaired, primary biliary cirrhosis, HEPATOLOGY *Elsewhere* Correspondence, 1027
Survival, prognostication, primary biliary cirrhosis, 111

Tamponade, balloon, *vs.* endoscopic sclerotherapy, HEPATOLOGY *Elsewhere*, 393
Taurine, uptake of bile acids, perfused rat liver, structure-activity relationship, 840
Taurocholate, transport, basolateral plasma membrane vesicles, 447
T cells
acute massive necrosis of liver, antibody/complement, HEPATOLOGY *Elsewhere*, 117
$CD4^+$,$Leu\text{-}8^+$, defective immunoregulation, primary biliary cirrhosis, 408
composition of mononuclear cell infiltrates, chronic active delta hepatitis, 911
Technetium-99m DISIDA, *vs.* endoscopic biliary manometry, sphincter of Oddi function, HEPATOLOGY *Elsewhere*, 895
Thallium, per rectum scintigraphy, portal pressure and portal perfusion, 262
Thiopental, infusion, intracranial hypertension, fulminant hepatic failure, 306
Threonine, high levels of acetaldehyde, nonalcoholic liver injury, 933
Thrombin, disseminated intravascular coagulation, cirrhosis, 103
Thrombosis
idiopathic portal hypertension, protein C deficiency, 902, 903
portal vein, myeloproliferative disorders, HEPATOLOGY *Elsewhere*, 390
Tin-protoporphyrin, sensitivity of human tissue heme oxygenase, synthetic metalloporphyrin, 365
$\alpha$-Tocopherol, lipid peroxidation, antioxidant defense systems, chronic ethanol feeding, 815
Transplantation
cold ischemic storage of rat livers, reperfusion injury, endothelial cells, 292
liver
aplastic anemia, HEPATOLOGY *Elsewhere*, 520
drug-binding proteins, HEPATOLOGY *Elsewhere*, 390
increased galactose clearance, 288
prognostic factors, primary sclerosing cholangitis, 430

Transplantation—*continued*
Mayo primary biliary cirrhosis, extramural cross-validation, 846
orthotopic liver, cytosolic estrogen-androgen receptor status, sex of donor, 861
reduced-size orthotopic liver, management of children, chronic liver disease, 867
rejection in liver, 978
D-Tryptophan-6-luteinizing hormone-releasing hormone, tumoral growth and plasma sex steroid levels, cirrhotic patients with hepatocellular carcinoma, 346
Tumor necrosis factor, endotoxin-induced release by monocytes, inhibition by bile acids, 454
Tumor necrosis factor-$\alpha$
$\kappa$B sequence-specific DNA-binding protein, hepatoblastoma cells, 1008
production by peripheral blood mononuclear cells, chronic liver disease, 769
regulation of hepatocyte gene expression, 1017

Ubiquitin, intermediate filament pathology, brain and liver, HEPATOLOGY *Elsewhere*, 514
Ultrasonography, angiographically undetected small hepatocellular carcinoma, follow-up and treatment, 1003
Ultrasound, diagnostic comparative studies, portal vein patency, HEPATOLOGY *Elsewhere*, 117
Uroporphyria, hepatic, mechanism, iron potentiation, 354
Ursodeoxycholic acid
effect on bile acid metabolism, primary biliary cirrhosis, 414
intraduodenal bile acid administration, biliary secretion, 134

Varices
active hemorrhage, tamponade *vs.* sclerotherapy, HEPATOLOGY *Elsewhere*, 393
bleeding, treatment comparisons, HEPATOLOGY *Elsewhere*, 517
esophageal
acute hemorrhage, somatostatin multicenter trial, 958
injection sclerotherapy, sucralfate, 279
gastric, successful endoscopic obturation, butyl cyanoacrylate, 488
Vasopression, association of transdermal nitroglycerin, variceal hemorrhage, 962
Viral promoters, heterologous, tissue-specific activity, primary rat hepatocytes, 781
Vitamin E, lipid peroxidation, antioxidant defense systems, chronic ethanol feeding, 815

Wilson's disease, presymptomatic, HEPATOLOGY *Elsewhere*, 892

0270-9139/89/1006-1045$02.00/0
HEPATOLOGY
Copyright © 1989 by The American Association for the Study of Liver Diseases
Vol. 10, No. 6, pp. 1045–1053, 1989
*Printed in U.S.A.*

# Author Index to Volume 10

Abou Hashieh, I., Rémy, L., Mathieu, S. and Gérolami, A. The effects of monensin on the transport of horseradish peroxidase into intracellular lumina in cultured rat hepatocytes, 61
Abraham, N. G., *see* Chernick, 365
Abroon, J., *see* Batta, 414
Ackerman, Z., Flugelman, M. Y., Wax, Y., Shouval, D. and Levy, M. Hepatitis during measles in young adults: Possible role of antipyretic drugs, 203
Acs, G., *see* Banerjee, 1008
Agrawal, N. M. Book Review, 522
Aiges, H., *see* Kahn, 21
Aihara, S., *see* Mitsui, 324
Akahane, Y., *see* Mitsui, 324
Akahane, Y., Tsuda, F. and Mayumi, M. Correspondence: To the Editor—Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of hepatitis B virus infection, 398
Alagille, D., *see* Labrune, 122
Aldini, R., Roda, A., Simoni, P., Lenzi, P. and Roda, E. Uptake of bile acids by perfused rat liver: Evidence of a structure-activity relationship, 840
Alexander, G. J. M., *see* Forbes, 306
Allende, E., *see* Buti, 907
Alonso, E. M., *see* Emond, 867
Alpert, E., *see* Michaletz, 829
Amatruda, J. M. and Salhanick, A. I. HEPATOLOGY *Elsewhere*—Insulin and steatonecrosis: Are they related?, 1024
Ansari, A., *see* Surh, 127
Anwer, M. S. Book Review, 259
Appelman, H. D., *see* Ruwart, 801
Arao, M., *see* Yoshioka, 769
Armstrong, J. McD., *see* Mackay, 389
Arora, R., *see* Batta, 414
Arroyo, V., *see* Ginès, 263
Arroyo, V., *see* Guarner, 788
Avinoah, E., *see* Klain, 873
Azorin, I., Miñana, M.-D., Felipo, V. and Grisolia, S. A simple animal model of hyperammonemia, 311

Babaev, V. R., Kosykh, V. A., Tsibulsky, V. P., Ivanov, V. O., Repin, V. S. and Smirnov, V. N. Binding and uptake of native and modified low-density lipoproteins by human hepatocytes in primary culture, 56
Babany, G., *see* Larrey, 168
Bacq, Y., *see* Moreau, 93
Bakker, E., *see* Lelie, 36
Balart, L. Book Review, 396
Ballet, F., *see* Guéchot, 346
Banerjee, R., Karpen, S., Siekevitz, M., Lengyel, G., Bauer, J. and Acs, G. Tumor necrosis factor-$\alpha$ induces a $\kappa$B sequence-specific DNA-binding protein in human hepatoblastoma HepG2 cells, 1008
Baraona, E., *see* Ma, 933
Barbara, L., *see* Gaiani, 1032
Barbara, L., *see* Saracco, 336
Bar-Meir, S. and Chamovitz, D. HEPATOLOGY *Elsewhere*—$^{99m}$Tc-DISIDA vs. endoscopic biliary manometry in assessing sphincter of Oddi function, 895
Bassendine, M. F., *see* James, 247
Bassendine, M. F., *see* Mitchison, 420
Bassendine, M. F., *see* Mutimer, 403
Batta, A. K., Salen, G., Arora, R., Shefer, S., Tint, G. S., Abroon, J., Eskreis, D. and Katz, S. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis, 414
Bauer, J., *see* Banerjee, 1008
Baum, H., *see* Flannery, 370
Beaver, S. J., *see* Wang, 39
Beaver, S. J., *see* Wiesner, 430
Belgiorno, J., *see* Mastaï, 941
Benhamou, J.-P., *see* Marcellin, 328
Benhamou, J.-P., *see* Ramond, 488
Benhamou, J.-P., *see* Valla, 482
Bernuau, J., *see* Ramond, 488
Bernuau, J., *see* Valla, 482
Berson, A., *see* Larrey, 168
Berthelot, P., *see* Marcellin, 328
Berthelot, P., *see* Pol, 342
Beutler, J. J., Koomans, H. A., Rabelink, T. J., Gaillard, C. A., Van Hattum, J., Boer, P. and Dorhout Mees, E. J. Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis, 148
Bianchi, G., *see* Marchesini, 253
Biempica, L., *see* Czaja, 795
Bijleveld, C. M. A., Vonk, R. J. and Kuipers, F. Correspondence: Reply, 1031
Bircher, J. Correspondence: To the Editor—Treatment of patients with benign recurrent intrahepatic cholestasis, 1030
Bodenheimer, H. Book Review, 395
Boer, P., *see* Beutler, 148
Bolondi, L., *see* Gaiani, 1032
Bonino, F., *see* Brunetto, 198
Bonino, F., *see* Negro, 916
Bonino, F., *see* Saracco, 336
Bonkovsky, H. L. Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells, 354
Bosch, J., Groszmann, R. J., García-Pagán, J. C., Terés, J., García-Tsao, G., Navasa, M., Mas, A. and Rodés, J. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial, 962
Bosch, J., *see* Mastai, 269
Bosch, J., *see* Pizcueta, 953
Bost, M. C. F., *see* van Berlo, 315
Boyer, J. L., *see* Corasanti, 8
Braillon, A., *see* Moreau, 93
Braillon, A., *see* Ozier, 473
Braillon, A., *see* Roulot, 477
Brault, A., *see* Mastaï, 941
Brechot, C., *see* Marcellin, 328
Brechot, C., *see* Pol, 342
Broelsch, C. E., *see* Emond, 867
Brook, M. G., Karayiannis, P. and Thomas, H. C. Which patients with chronic hepatitis B virus infection will respond to $\alpha$-interferon therapy? A statistical analysis of predictive factors, 761
Bruix, J., *see* Mastai, 269
Brumfitt, W., *see* Flannery, 370
Brunetto, M. R., Oliveri, F., Rocca, G., Criscuolo, D., Chiaberge, E., Capalbo, M., David, E., Verme, G. and Bonino, F. Natural course

and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen, 198
Burroughs, A. K., *see* Flannery, 370
Buti, M., Esteban, R., Jardi, R., Rodriguez-Frias, F., Casacuberta, J., Esteban, J. I., Allende, E. and Guardia, J. Chronic delta hepatitis: Detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication, 907
Butler, P., *see* Flannery, 370
Butterworth, R. F., *see* Pomier-Layrargues, 969
Buurman, W. A., *see* Greve, 454

Cai, Z., Shi, Z., Sherman, M. and Sun, A. M. Development and evaluation of a system of microencapsulation of primary rat hepatocytes, 855
Caldwell-Kenkel, J. C., Currin, R. T., Tanaka, Y., Thurman, R. G. and Lemasters, J. J. Reperfusion injury to endothelial cells following cold ischemic storage of rat livers, 292
Cancellieri, C., *see* Saracco, 336
Cap, L., *see* Michaletz, 829
Capalbo, M., *see* Brunetto, 198
Carmichael, F. J., *see* Kawasaki, 273
Carmichael, F. J., *see* Verma-Ansil, 946
Carr, J. M. Special Article—Disseminated intravascular coagulation in cirrhosis, 103
Casacuberta, J., *see* Buti, 907
Castot, A., *see* Larrey, 168
Chamovitz, D., *see* Bar-Meir, 895
Chang, L.-j., Dienstag, J., Ganem, D. and Varmus, H. Detection of antibodies against hepatitis B virus polymerase antigen in hepatitis B virus-infected patients, 332
Chang, T.-T., *see* Tsai, 283
Charles, R., *see* Lamers, 72
Charuzi, I., *see* Klain, 873
Chelliah, J., *see* Flannery, 370
Chernick, R. J., Martasek, P., Levere, R. D., Margreiter, R. and Abraham, N. G. Sensitivity of human tissue heme oxygenase to a new synthetic metalloporphyrin, 365
Chevalier, M., *see* Marcellin, 328
Chiaberge, E., *see* Brunetto, 198
Christensen, E. Editorial—Prognostication in primary biliary cirrhosis: Relevance to the individual patient, 111
Chu, C.-M. and Liaw, Y.-F. Studies on the composition of the mononuclear cell infiltrates in liver from patients with chronic active delta hepatitis, 911
Churchill, N. D., *see* Michalak, 44
Chytrý, V., *see* O'Hare, 207
Civeira, M. P., *see* Suou, 408
Classen, M., *see* Knyrim, 134
Coleman, A. E., *see* Hearn, 822
Combes, B. Editorial—Prednisolone for primary biliary cirrhosis—Good news, bad news, 511
Conn, H. O., *see* Eriksson, 228
Conn, H. O., *see* Valenzuela, 958
Conn, H. O. HEPATOLOGY *Elsewhere*— Portacaval anastomosis: The longest shunt, 1026
Cooper, A. J. L., *see* Hearn, 822
Coppel, R. L., *see* Surh, 127
Corasanti, J. G., Smith, N. D., Gordon, E. R. and Boyer, J. L. Protein kinase C agonists inhibit bile secretion independently of effects on the microcirculation in the isolated perfused rat liver, 8
Cova, L., *see* Fourel, 186
Criscuolo, D., *see* Brunetto, 198
Crocè, L. S., *see* Tiribelli, 998
Currin, R. T., *see* Caldwell-Kenkel, 292
Czaja, A. J., Hay, J. E. and Rakela, J. Correspondence: Reply, 524
Czaja, A. J., *see* Wang, 39
Czaja, M. J., Weiner, F. R., Takahashi, S., Giambrone, M.-A., van der Meide, P. H., Schellekens, H., Biempica, L. and Zern, M. A. γ-Interferon treatment inhibits collagen deposition in murine schistosomiasis, 795

Danner, D. J., *see* Surh, 127
Dansette, P., *see* Larrey, 168
D'Arienzo, A. and Mazzacca, G. Correspondence: Reply, 262
Datta, R., *see* Panda, 466
Daum, F., *see* Kahn, 21
David, E., *see* Brunetto, 198
Dawling, S., *see* Forbes, 306
DeCarli, L. M., *see* Lieber, 501
Deckert, J., *see* Rössle, 143
Degos, F., *see* Marcellin, 328
Degott, C., *see* Marcellin, 328
Degott, C., *see* Ramond, 488
de Groot, C. S. M., *see* Lelie, 36
de Lacy, A. M., *see* Pizcueta, 953
de Morais, S. M. F. and Wells, P. G. Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency, 163
Denk, H., Zatloukal, K. and Preisegger, K.-H. HEPATOLOGY *Elsewhere*—Ubiquitin—a common denominator in intermediate filament pathology of brain and liver?, 514
de Villiers, J., *see* Fang, 781
Dhurandhar, N. R. Book Review, 901
Di Bisceglie, A., *see* Negro, 916
Di Bisceglie, A. M. and Negro, F. Editorial—Diagnosis of hepatitis delta virus infection, 1014
Dickson, E. R., Grambsch, P. M., Fleming, T. R., Fisher, L. D. and Langworthy, A. Prognosis in primary biliary cirrhosis: Model for decision making, 1
Dickson, E. R., *see* Grambsch, 846
Dickson, E. R., *see* Surh, 127
Dickson, E. R., *see* Wiesner, 430
Dienstag, J., *see* Chang, 332
Dienstag, J. L. Editorial—Passive-active immunoprophylaxis after percutaneous exposure to hepatitis B virus, 385
Dietze, E., *see* Krell, 300
Dorhout Mees, E. J., *see* Beutler, 148
Dubois, F., *see* Pol, 342
Duncan, R., *see* O'Hare, 207

Eagon, P. K., *see* Kahn, 861
Eckert, E. R. Book Review, 1028
Eichberg, J. W., *see* Jacob, 921
Elias, E. HEPATOLOGY *Elsewhere* Correspondence—Impaired sulfoxidation in primary biliary cirrhosis, 1027
Elliott, D. W. HEPATOLOGY *Elsewhere*—Gallstone pancreatitis: When is the optimal time for intervention?, 1022
Emonard, H. and Grimaud, J.-A. Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis, 77
Emond, J. C., Whitington, P. F., Thistlethwaite, J. R., Alonso, E. M. and Broelsch, C. E. Reduced-size orthotopic liver transplantation: Use in the management of children with chronic liver disease, 867
Epstein, O. HEPATOLOGY *Elsewhere*—Presymptomatic Wilson's disease: Further questions and comments, 892
Eriksson, L. S. and Conn, H. O. Special Article—Branched-chain amino acids in the management of hepatic encephalopathy: An analysis of variants, 228
Erlinger, S. Book Review, 260
Eskreis, D., *see* Batta, 414
Esteban, J. I., *see* Buti, 907
Esteban, R., *see* Buti, 907

Fabry, T. L., *see* Valenzuela, 958

Fang, X.-j., Keating, A., de Villiers, J. and Sherman, M. Tissue-specific activity of heterologous viral promoters in primary rat hepatocytes and Hep G2 cells, 781
Farrell, G. C., *see* Williams, 192
Felipo, V., *see* Azorin, 311
Fevery, J., *see* Sieg, 14
Fisher, L. D., *see* Dickson, 1
Fisher, L. D., *see* Wiesner, 430
Flannery, G. R., Burroughs, A. K., Butler, P., Chelliah, J., Hamilton-Miller, J., Brumfitt, W. and Baum, H. Antimitochondrial antibodies in primary biliary cirrhosis recognize both specific peptides and shared epitopes of the M2 family of antigens, 370
Flejou, J.-F., *see* Valla, 482
Fleming, T. R., *see* Dickson, 1
Fleming, T. R., *see* Grambsch, 846
Fleming, T. R., *see* Wiesner, 430
Flendrig, J. G., *see* Peltenburg, 833
Flugelman, M. Y., *see* Ackerman, 203
Fogel, M. R., *see* Valenzuela, 958
Forbes, A., Alexander, G. J. M., O'Grady, J. G., Keays, R., Gullan, R., Dawling, S. and Williams, R. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure, 306
Fourel, I., Gripon, P., Hantz, O., Cova, L., Lambert, V., Jacquet, C., Watanabe, K., Fox, J., Guillouzo, C. and Trepo, C. Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: A useful system for antiviral testing, 186
Fox, J., *see* Fourel, 186
Francavilla, A., *see* Kahn, 861
Fraser, D., *see* Klain, 873
French, S. W. and Tsukamoto, H. HEPATOLOGY *Elsewhere* Correspondence: To the Editor: Animal models for alcoholic liver disease, 898
Freneaux, E., *see* Larrey, 168
Fuchs, K., Heberger, C., Weimer, T. and Roggendorf, M. Characterization of woodchuck hepatitis virus DNA and RNA in the hepatocellular carcinomas of woodchucks, 215
Fujikawa, M., *see* Onishi, 349
Furt, E., *see* Lamers, 72
Furuta, T., *see* Kanematsu, 98
Fusamoto, H., *see* Sasaki, 494
Fussey, S. P. M., *see* Mutimer, 403

Gaiani, S., Bolondi, L. and Barbara, L. Correspondence: Reply, 1032
Gaillard, C. A., *see* Beutler, 148
Galle, P. R., Schlicht, H.-J., Kuhn, C. and Schaller, H. Replication of duck hepatitis B virus in primary duck hepatocytes and its dependence on the state of differentiation of the host cell, 459
Ganem, D., *see* Chang, 332
García-Pagán, J. C., *see* Bosch, 962
García-Tsao, G., *see* Bosch, 962
García-Tsao, G., *see* Orozco, 903
Gasbarrini, G., *see* Saracco, 336
Gaudin, C., *see* Moreau, 93
Gaudin, C., *see* Ozier, 473
Gaudin, C., *see* Roulot, 477
Gelderblom, H., *see* Möller, 179
Gerber, M. A., *see* Malter, 1017
Gerbes, A. L. HEPATOLOGY *Elsewhere*—Augmentation of the natriuretic response to atrial natriuretic factor in cirrhosis, 897
Gerin, J. L., *see* Negro, 916
Gerken, G., *see* Mayet, 24
Gerok, W., *see* Leser, 66
Gérolami, A., *see* Abou Hashieh, 61
Gershwin, M. E., *see* Surh, 127
Ghishan, F. K. Correspondence: Reply, 122
Giambrone, M.-A., *see* Czaja, 795
Giarelli, L., *see* Tiribelli, 998
Giboudeau, J., *see* Guéchot, 346
Giguère, J.-F., *see* Pomier-Layrargues, 969
Gilbert, J. Book Review, 522
Giles, G., *see* Kawasaki, 273
Gimson, A. E. S., *see* Polson, 279
Ginès, P. and Arroyo, V. Correspondence: Reply, 263
Giorda, L., *see* Saracco, 336
Girod, C., *see* Roulot, 477
Glaser, J., *see* Morecki, 515
Go, V. L. W., *see* Wang, 39
Godiwala, T. Book Review, 121
Goerig, M., Wernze, H., Kommerell, B. and Grün, M. Increased bioavailability of enzymes of eicosanoid synthesis in hepatic and extrahepatic tissues after portacaval shunting, 154
Goldstein, J., *see* Klain, 873
Gonwa, T. A., *see* Klintmalm, 978
Gordon, E. R., *see* Corasanti, 8
Goudeau, A., *see* Pol, 342
Gouma, D. J., *see* Greve, 454
Govindarajan, S., Gupta, S., Valinluck, B. and Redeker, A. G. Correlation of IgM anti-hepatitis D virus (HDV) to HDV RNA in sera of chronic HDV, 34
Grambsch, P. M., Dickson, E. R., Kaplan, M., LeSage, G., Fleming, T. R. and Langworthy, A. L. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability, 846
Grambsch, P. M., *see* Dickson, 1
Grambsch, P. M., *see* Wiesner, 430
Greim, M. H. and Schwarz, L. Book Review, 260
Greve, J. W., Gouma, D. J. and Buurman, W. A. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: An *in vitro* study, 454
Griffith, O. W., *see* Hearn, 822
Grimaud, J.-A., *see* Emonard, 77
Gripon, P., *see* Fourel, 186
Grisolia, S., *see* Azorin, 311
Groszmann, R. J., *see* Bosch, 962
Grün, M., *see* Goerig, 154
Guardia, J., *see* Buti, 907
Guarner, F., Wallace, J. L., MacNaughton, W. K., Ibbotson, G. C., Arroyo, V. and Rodés, J. Endotoxin-induced ascites formation in the rat: Partial mediation by platelet-activating factor, 788
Guéchot, J., Peigney, N., Ballet, F., Vaubourdolle, M., Giboudeau, J. and Poupon, R. Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma, 346
Guillouzo, C., *see* Fourel, 186
Gullan, R., *see* Forbes, 306
Gupta, S., *see* Govindarajan, 34

Habersetzer, F., *see* Larrey, 168
Hadengue, A., *see* Moreau, 93
Hadengue, A., *see* Ozier, 473
Hahn, E. G., *see* Milani, 84
Hahn, E. G., *see* Ruwart, 801
Ham, H. R., *see* Urbain, 262
Hamilton-Miller, J., *see* Flannery, 370
Hantz, O., *see* Fourel, 186
Hasegawa, M., Yamada, S. and Hirayama, C. Fasting plasma caffeine level in cirrhotic patients: Relation to plasma levels of catecholamines and renin activity, 973
Hasuo, K., *see* Kanematsu, 98
Hay, J. E., *see* Czaja, 524
Hayashi, N., *see* Sasaki, 494
Hayes, P. C., *see* Polson, 279

Hayllar, K., *see* Polson, 279
Hearn, T. J., Coleman, A. E., Lai, J. C. K., Griffith, O. W. and Cooper, A. J. L. Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portacaval-shunted rats, 822
Heathcote, E. J. L. Book Review, 120
Heberger, C., *see* Fuchs, 215
Heirwegh, K. P. M., *see* Sieg, 14
Henderson, J. M., Millikan, W. J., Hooks, M., Noe, B., Kutner, M. H. and Warren, W. D. Increased galactose clearance after liver transplantation: A measure of increased blood flow through the denervated liver?, 288
Henley, K. S., *see* Ruwart, 801
Henriksen, J. H. HEPATOLOGY *Elsewhere*—Endogenous opioid peptides in the pathogenesis of ascites, 896
Henze, G., *see* Möller, 179
Herberman, R. B., *see* Schwarz, 221
Herbst, H., *see* Milani, 84
Hermens, W. T., *see* Peltenburg, 833
Hernández-Muñoz, R., *see* Ma, 933
Hess, G., *see* Mayet, 24
Hickman, R. Correspondence: Reply, 527
Hilberts, A., *see* Lamers, 72
Hirayama, C., *see* Hasegawa, 973
Hirota, S., *see* Nishiguchi, 29
Holstege, A., *see* Læser, 66
Hoofnagle, J. H., *see* Negro, 916
Hooks, M., *see* Henderson, 288
Hopf, U., *see* Möller, 179
Hosking, S. W. HEPATOLOGY *Elsewhere*—Congestive gastropathy in portal hypertension: Variations in prevalence, 257
Housset, C., *see* Pol, 342
Huet, P.-M., *see* Mastaï, 941
Hume, I. C., *see* O'Hare, 207
Hunter, E. B., *see* Wiesner, 430
Husberg, B. S., *see* Klintmalm, 978

Ibbotson, G. C., *see* Guarner, 788
Inoue, M., *see* Yoshioka, 769
Israel, Y., *see* Kawasaki, 273
Ito, T., *see* Sasaki, 494
Ivanov, V. O., *see* Babaev, 56
Iwano, K., *see* Mitsui, 324
Iwatsuki, S., *see* Schwarz, 221

Jacob, J. R., Eichberg, J. W. and Lanford, R. E. *In vitro* replication and expression of hepatitis B virus from chronically infected primary chimpanzee hepatocytes, 921
Jacquet, C., *see* Fourel, 186
James, O. F. W., *see* Mitchison, 420
James, O. F. W., *see* Mutimer, 403
James, O. F. W., Yeaman, S. J. and Bassendine, M. F. Editorial—Molecular aspects of the M2 autoantigens in primary biliary cirrhosis: What a difference a year makes, 247
James, S. P., *see* Suou, 408
Janssen, M. A., *see* van Berlo, 315
Janzen, J. W. G., *see* Lamers, 72
Jardi, R., *see* Buti, 907
Jones, E. A., *see* Rössle, 143
Jones, E. A., *see* Suou, 408
Jonges, G. N., *see* Lamers, 72
Jüngst, D. HEPATOLOGY *Elsewhere*—The differentiation of cholesterol and pigment gallstones, 518

Kahn, D., Zeng, Q., Makowka, L., Murase, N., Nakajima, Y., Eagon, P. K., Francavilla, A., Starzl, T. E. and Van Thiel, D. H. Orthotopic liver transplantation and the cytosolic estrogen-androgen receptor status of the liver: The influence of the sex of the donor, 861
Kahn, E., Markowitz, J., Aiges, H. and Daum, F. Human ontogeny of the bile duct to portal space ratio, 21
Kakumu, S., *see* Yoshioka, 769
Kamada, T., *see* Sasaki, 494
Kanematsu, T., Furuta, T., Takenaka, K., Matsumata, T., Yoshida, Y., Nishizaki, T., Hasuo, K. and Sugimachi, K. A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma, 98
Kanematsu, T., *see* Sonoda, 1003
Kanof, M. E., *see* Suou, 408
Kaplan, M., *see* Grambsch, 846
Kaplan, M. M., *see* Knox, 392
Karayiannis, P., *see* Brook, 761
Karpen, S., *see* Banerjee, 1008
Kasahara, A., *see* Sasaki, 494
Kato, S., *see* Kawase, 815
Katz, S., *see* Batta, 414
Kaur, J., *see* Panda, 466
Kawasaki, T., Carmichael, F. J., Giles, G., Saldivia, V., Israel, Y. and Orrego, H. Effects of propylthiouracil and methimazole on splanchnic hemodynamics in awake and unrestrained rats, 273
Kawase, T., Kato, S. and Lieber, C. S. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding, 815
Keating, A., *see* Fang, 781
Keays, R., *see* Forbes, 306
Kelly, P. J., *see* Mutimer, 403
Kim, K. Y., *see* Ruwart, 801
Klain, J., Fraser, D., Goldstein, J., Peiser, J., Avinoah, E., Ovnat, A. and Charuzi, I. Liver histology abnormalities in the morbidly obese, 873
Klintmalm, G. B. G., Nery, J. R., Hosberg, B. S., Gonwa, T. A. and Tillery, G. W. Rejection in liver transplantation, 978
Klion, F. M. Book Review, 121, 1029
Knobler, E., Poh-Fitzpatrick, M. B., Kravetz, D., Vincent, W. R., Muller-Eberhard, U. and Vincent, S. H. Interaction of hemopexin, albumin and liver fatty acid-binding protein with protoporphyrin, 995
Knoflach, P., *see* Müller, 928
Knox, T. A. and Kaplan, M. M. HEPATOLOGY *Elsewhere*— Myeloproliferative disorders in portal vein thrombosis in adults, 392
Knyrim, K., Vakil, N., Pfab, R. and Classen, M. The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man, 134
Kobayashi, K., *see* Nishiguchi, 29
Koblin, D. D. Correspondence: To the Editor—Nitrous oxide interferes with the aminopyrine breath test, 526
Kommerell, B., *see* Goerig, 154
Kommerell, B., *see* Sieg, 14
Kong, C.-W., *see* Tsai, 283
Konikoff, F., Pecht, M., Theodor, E. and Shoenfeld, Y. Correspondence: To the Editor—Primary biliary cirrhosis: Lymphocyte subsets and function in a time frame, 525
Koomans, H. A., *see* Beutler, 148
Kopeček, J., *see* O'Hare, 207
Kopečková, P., *see* O'Hare, 207
Kosykh, V. A., *see* Babaev, 56
Kravetz, D., *see* Knobler, 995
Kravetz, D., *see* Mastai, 269
Kravetz, D., *see* Pizcueta, 953
Krell, H. and Dietze, E. Hemodynamic and metabolic responses to leukotriene $C_4$ in isolated perfused rat liver, 300
Kuhn, C., *see* Galle, 459
Kuipers, F., *see* Bijleveld, 1031
Kuroki, T., *see* Nishiguchi, 29
Kurtzman, N. A. Book Review, 900

Kutner, M. H., *see* Henderson, 288

Labrune, P., Odièvre, M. and Alagille, D. Correspondence: To the Editor—Influence of sex and breastfeeding on liver disease in $\alpha_1$-antitrypsin deficiency, 122
Lai, J. C. K., *see* Hearn, 822
Lambert, V., *see* Fourel, 186
Lamers, W. H., Hilberts, A., Furt, E., Smith, J., Jonges, G. N., van Noorden, C. J. F., Janzen, J. W. G., Charles, R. and Moorman, A. F. M. Hepatic enzymic zonation: A reevaluation of the concept of the liver acinus, 72
Lanford, R. E., *see* Jacob, 921
Langworthy, A., *see* Dickson, 1
Langworthy, A. L., *see* Grambsch, 846
Larrey, D., Berson, A., Habersetzer, F., Tinel, M., Castot, A., Babany, G., Lettéron, P., Freneaux, E., Loeper, J., Dansette, P. and Pessayre, D. Genetic predisposition to drug hepatotoxicity: Role in hepatitis caused by amineptine, a tricyclic antidepressant, 168
LaRusso, N. F., *see* Wiesner, 430
LaRusso, N. F., *see* Yamazaki, 877
Lasker, J. M., *see* Tsutsumi, 437
Lattore, V., *see* Saracco, 336
Lauterburg, B. H., *see* Michaletz, 829
Lavoie, J., *see* Pomier-Layrargues, 969
Lay, C.-S., *see* Tsai, 283
Lebrec, D., *see* Moreau, 93
Lebrec, D., *see* Ozier, 473
Lebrec, D., *see* Roulot, 477
Lebrec, D., *see* Valla, 482
Lee, F.-Y., *see* Tsai, 283
Lee, S.-D., *see* Tsai, 283
Lee, S. S. Correspondence: To the Editor—Timing of postprandial hemodynamic events in cirrhosis, 1032
Lee, S. S. HEPATOLOGY *Elsewhere*—Alcohol infusion to measure hepatic blood flow: Vanquishing the bête noire?, 1021
Lelie, P. N., van Amelsfoort, P. J. A. J., de Groot, C. S. M., Bakker, E., Schaasberg, W., Niessen, J. C. M. and Reesink, H. W. Lack of immune potentiation by complexing HBsAg in a heat-inactivated hepatitis B vaccine with antibody in hepatitis B immunoglobulin, 36
Lemasters, J. J., *see* Caldwell-Kenkel, 292
Lengyel, G., *see* Banerjee, 1008
Lenzi, P., *see* Aldini, 840
LeSage, G., *see* Grambsch, 846
Leser, H.-G., Holstege, A. and Gerok, W. The role of nonparenchymal and parenchymal liver cells in the catabolism of extracellular purines, 66
Lettéron, P., *see* Larrey, 168
Levere, R. D., *see* Chernick, 365
Levine, J., *see* Valenzuela, 958
Levy, M., *see* Ackerman, 203
Liaw, Y.-F. Correspondence: To the Editor—AFP in chronic hepatitis B virus infection, 398
Liaw, Y.-F., *see* Chu, 911
Lieber, C. S., DeCarli, L. M. and Sorrell, M. F. Special Article—Experimental methods of ethanol administration, 501
Lieber, C. S., *see* Kawase, 815
Lieber, C. S., *see* Ma, 933
Lieber, C. S., *see* Tsutsumi, 437
Lin, H.-C., *see* Tsai, 283
Lin, R. C. and Lumeng, L. Further studies on the 37 kD liver protein-acetaldehyde adduct that forms *in vivo* during chronic alcohol ingestion, 807
Lindor, K. D. Correspondence: Reply, 526
Litwin, M. Book Review, 397
Lo, K.-J., *see* Tsai, 283
Loeper, J., *see* Larrey, 168
Lok, A. Correspondence: Reply, 399
Lok, A. HEPATOLOGY *Elsewhere*—Acute viral hepatitis in chronic carriers of hepatitis B virus: Different patterns in different places, 252
Ludwig, J., *see* Wiesner, 430
Lumeng, L., *see* Lin, 807

Ma, X.-l., Baraona, E., Hernández-Muñoz, R. and Lieber, C. S. High levels of acetaldehyde in nonalcoholic liver injury after threonine or ethanol administration, 933
MacCarty, R. L., *see* Wiesner, 430
Mackay, I. R., Rowley, M. J. and Armstrong, J. McD. HEPATOLOGY *Elsewhere*—Identity of the M2 autoantigens in primary biliary cirrhosis, 389
MacNaugton, W. K., *see* Guarner, 788
Makowka, L., *see* Kahn, 861
Malcolm, A. J., *see* Mitchison, 420
Malter, J. S. and Gerber, M. A. Editorial—Regulation of hepatocyte gene expression: Progress on the horizon, 1017
Manns, M., *see* Mayet, 24
Marcellin, P., Ouzan, D., Degos, F., Brechot, C., Metman, E.-H., Degott, C., Chevalier, M., Berthelot, P., Trepo, C. and Benhamou, J.-P. Randomized controlled trial of adenine arabinoside 5′-monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients, 328
Marchesini, G. and Bianchi, G. HEPATOLOGY *Elsewhere*—Carbohydrate metabolism in hepatocellular carcinoma: Where does the glucose go?, 253
Margreiter, R., *see* Chernick, 365
Markowitz, J., *see* Kahn, 21
Martasek, P., *see* Chernick, 365
Mas, A., *see* Bosch, 962
Mastai, R., Bosch, J., Bruix, J., Navasa, M., Kravetz, D. and Rodés, J. $\beta$-Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis, 269
Mastaï, R., Huet, P.-M., Brault, A. and Belgiorno, J. The rat liver microcirculation in alcohol-induced hepatomegaly, 941
Masuko, K., *see* Mitsui, 324
Mathieu, S., *see* Abou Hashieh, 61
Matsumata, T., *see* Kanematsu, 98
Matsunaga, Y., *see* Onishi, 349
Matsuura, Y., *see* Onishi, 349
Mayet, W.-J., Hess, G., Gerken, G., Rossol, S., Voth, R., Manns, M. and Meyer zum Büschenfelde, K.-H. Treatment of chronic type B hepatitis with recombinant $\alpha$-interferon induces autoantibodies not specific for autoimmune chronic hepatitis, 24
Mayumi, M., *see* Akahane, 398
Mayumi, M., *see* Mitsui, 324
Mazzella, G., *see* Saracco, 336
Melato, M., *see* Tiribelli, 998
Metman, E.-H., *see* Marcellin, 328
Meyer zum Büschenfelde, K.-H., *see* Mayet, 24
Mezey, E. HEPATOLOGY *Elsewhere* Correspondence: Response of the Commenter, 899
Michalak, T. I., Snyder, R. L. and Churchill, N. D. Characterization of the incorporation of woodchuck hepatitis virus surface antigen into hepatocyte plasma membrane in woodchuck hepatitis and in the virus-induced hepatocellular carcinoma, 44
Michaletz, P. A., Cap, L., Alpert, E. and Lauterburg, B. H. Assessment of mitochondrial function *in vivo* with a breath test utilizing $\alpha$-ketoisocaproic acid, 829
Milani, S., Herbst, H., Schuppan, D., Hahn, E. G. and Stein, H. *In situ* hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: Evidence for predominant expression in nonparenchymal liver cells, 84
Millikan, W. J., *see* Henderson, 288

Mills, P. R., *see* Valenzuela, 958
Miñana, M.-D., *see* Azorin, 311
Mitchison, H. C., Bassendine, M. F., Malcolm, A. J., Watson, A. J., Record, C. O. and James, O. F. W. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss, 420
Mitsui, T., Iwano, K., Suzuki, S., Yamazaki, C., Masuko, K., Tsuda, F., Aihara, S., Akahane, Y., Miyakawa, Y. and Mayumi, M. Combined hepatitis B virus infection in hemodialysis staff members: Comparison with immune globulin without vaccine in historical controls, 324
Miyakawa, Y., *see* Mitsui, 324
Möller, B., Hopf, U., Stemerowicz, R., Henze, G. and Gelderblom, H. HBcAg expressed on the surface of circulating Dane particles in patients with hepatitis B virus infection without evidence of anti-HBc formation, 179
Moorman, A. F. M., *see* Lamers, 72
Moreau, R., Roulot, D., Braillon, A., Gaudin, C., Hadengue, A., Bacq, Y. and Lebrec, D. Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: Evidence for an impaired cardiopulmonary baroreflex function, 93
Morecki, R. and Glaser, J. HEPATOLOGY *Elsewhere*—Reovirus 3 and neonatal biliary disease: Discussion of divergent results, 515
Moreno-Otero, R., *see* Suou, 408
Morgan, D. J. and Smallwood, R. A. HEPATOLOGY *Elsewhere*—Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?, 893
Morita, Y., *see* Sasaki, 494
Mosnier, J.-F., *see* Ramond, 488
Müller, C., Knoflach, P. and Zielinski, C. C. Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease, 928
Muller-Eberhard, U., *see* Knobler, 995
Murase, N., *see* Kahn, 861
Mutimer, D. J., Fussey, S. P. M., Yeaman, S. J., Kelly, P. J., James, O. F. W. and Bassendine, M. F. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis, 403

Nakajima, S., *see* Nishiguchi, 29
Nakajima, Y., *see* Kahn, 861
Nakanuma, Y., *see* Terada, 851
Nakanuma, Y. and Sasaki, M. Expression of blood group-related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases, 174
Navasa, M., *see* Bosch, 962
Navasa, M., *see* Mastai, 269
Nayak, N. C., *see* Panda, 466
Nayak, N. C. Correspondence: To the Editor—Idiopathic portal hypertension (noncirrhotic portal fibrosis), thrombosis in portal venous system and protein C deficiency, 902
Negro, F., Bonino, F., Di Bisceglie, A., Hoofnagle, J. H. and Gerin, J. L. Intrahepatic markers of hepatitis delta virus infection: A study by *in situ* hybridization, 916
Negro, F., *see* Di Bisceglie, 1014
Nery, J. R., *see* Klintmalm, 978
Niessen, J. C. M., *see* Lelie, 36
Nishiguchi, S., Kuroki, T., Otani, S., Takeda, T., Hirota, S., Shimizu, Y., Nakajima, S., Saito, S., Shiomi, S. and Kobayashi, K. Relationship of the effects of interferon in chronic hepatitis B and the induction of 2′,5′-oligoadenylate synthetase, 29
Nishizaki, T., *see* Kanematsu, 98
Noe, B., *see* Henderson, 288
Nolan, J. P. Editorial—Intestinal endotoxins as mediators of hepatic injury—an idea whose time has come again, 887
Novak, D. A., Ryckman, F. C. and Suchy, F. J. Taurocholate transport by basolateral plasma membrane vesicles isolated from human liver, 447

Odièvre, M., *see* Labrune, 122
O'Grady, J. G., *see* Forbes, 306
O'Hare, K. B., Hume, I. C., Scarlett, L., Chytrý, V., Kopečková, P., Kopeček, J. and Duncan, R. Effect of galactose on interaction of *N*-(2-hydroxypropyl)methacrylamide copolymers with hepatoma cells in culture: Preliminary application to an anticancer agent, daunomycin, 207
Ohnishi, K., *see* Tiribelli, 998
Okuda, K., *see* Tiribelli, 998
Okuda, K. Correspondence: To the Editor—Idiopathic portal hypertension and protein C deficiency, 903
Okuda, K. HEPATOLOGY *Elsewhere*—Acute massive necrosis of the liver induced by antibody/complement, not by T-cells, 118
Oliveri, F., *see* Brunetto, 198
Onishi, S., Saibara, T., Fujikawa, M., Sakaeda, H., Matsuura, Y., Matsunaga, Y. and Yamamoto, Y. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma, 349
Orozco, H., Garcia-Tsao, G. and Takahashi, T. Correspondence: Reply, 903
Orrego, H., *see* Kawasaki, 273
Orrego, H., *see* Verma-Ansil, 946
Otani, S., *see* Nishiguchi, 29
Ouzan, D., *see* Marcellin, 328
Ovnat, A., *see* Klain, 873
Ozier, Y., Braillon, A., Gaudin, C., Roulot, D., Hadengue, A. and Lebrec, D. Hepatic denervation alters hemodynamic response to hemorrhage in conscious rats, 473
Ozier, Y., *see* Roulot, 477

Panda, S. K., Datta, R., Kaur, J., Zuckerman, A. J. and Nayak, N. C. Enterically transmitted non-A, non-B hepatitis: Recovery of virus-like particles from an epidemic in South Delhi and transmission studies in rhesus monkeys, 466
Pecht, M., *see* Konikoff, 525
Peigney, N., *see* Guéchot, 346
Peiser, J., *see* Klain, 873
Peltenburg, H. G., Hermens, W. T., Willems, G. M., Flendrig, J. G. and Schmidt, E. Estimation of the fractional catabolic rate constants for the elimination of cytosolic liver enzymes from plasma, 833
Pessayre, D., *see* Larrey, 168
Peters, K. M., *see* Ruwart, 801
Pfab, R., *see* Knyrim, 134
Pizcueta, M. P., de Lacy, A. M., Kravetz, D., Bosch, J. and Rodés, J. Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotic rats, 953
Poh-Fitzpatrick, M. B., *see* Knobler, 995
Pol, S., Dubois, F., Roingeard, P., Zignego, L., Housset, C., Brechot, C., Goudeau, A. and Berthelot, P. Hepatitis delta virus infection in French male HBsAg-positive homosexuals, 342
Polson, R. J., Westaby, D., Gimson, A. E. S., Hayes, P. C., Stellon, A. J., Hayllar, K. and Williams, R. Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices, 279
Pomier-Layrargues, G., Giguère, J.-F., Lavoie, J., Willems, B. and Butterworth, R. F. Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction, 969
Posillico, J. T., *see* Valenzuela, 958
Poupon, R., *see* Guéchot, 346
Preisegger, K.-H., *see* Denk, 514
Prindiville, T., *see* Surh, 127
Purcell, R. H., *see* Shimizu, 764

Rabelink, T. J., *see* Beutler, 148

Rabeneck, L. HEPATOLOGY *Elsewhere*—Comparison of treatments of bleeding varices: Effects of differences between treatment intended and treatment received, 517
Raedsch, R., *see* Sieg, 14
Raise, E., *see* Saracco, 336
Rakela, J., *see* Czaja, 524
Ramond, M.-J., Valla, D., Mosnier, J.-F., Degott, C., Bernuau, J., Rueff, B. and Benhamou, J.-P. Successful endoscopic obturation of gastric varices with butyl cyanoacrylate, 488
Rascher, W., *see* Tulassay, 263
Record, C. O., *see* Mitchison, 420
Redeker, A. G., *see* Govindarajan, 34
Reed, D. J., *see* Thomas, 375
Reesink, H. W., *see* Lelie, 36
Rémy, L., *see* Abou Hashieh, 61
Repin, V. S., *see* Babaev, 56
Riely, C. A. Book Review, 120
Rigas, B. HEPATOLOGY *Elsewhere*—The evolving spectrum of amiodarone hepatotoxicity, 116
Rizzetto, M., *see* Saracco, 336
Rocca, G., *see* Brunetto, 198
Rocca, G., *see* Saracco, 336
Roche, T. E., *see* Surh, 127
Roda, A., *see* Aldini, 840
Roda, E., *see* Aldini, 840
Roda, E., *see* Saracco, 336
Rodés, J., *see* Bosch, 962
Rodés, J., *see* Guarner, 788
Rodés, J., *see* Mastai, 269
Rodés, J., *see* Pizcueta, 953
Rodriguez-Frias, F., *see* Buti, 907
Roggendorf, M., *see* Fuchs, 215
Roingeard, P., *see* Pol, 342
Rosina, F., *see* Saracco, 336
Rosman, A. S., *see* Tsutsumi, 437
Rössle, M., Deckert, J. and Jones, E. A. Autoradiographic analysis of GABA-benzodiazepine receptors in an animal model of acute hepatic encephalopathy, 143
Rossol, S., *see* Mayet, 24
Roulot, D., Braillon, A., Gaudin, C., Ozier, Y., Girod, C. and Lebrec, D. Mechanisms of a clonidine-induced decrease in portal pressure in normal and cirrhotic conscious rats, 477
Roulot, D., *see* Moreau, 93
Roulot, D., *see* Ozier, 473
Rowley, M. J., *see* Mackay, 389
Rueff, B., *see* Ramond, 488
Rueff, B., *see* Valla, 482
Rush, B. D., *see* Ruwart, 801
Ruwart, M. J., Wilkinson, K. F., Rush, B. D., Vidmar, T. J., Peters, K. M., Henley, K. S., Appelman, H. D., Kim, K. Y., Schuppan, D. and Hahn, E. G. The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat, 801
Ryckman, F. C., *see* Novak, 447

Sadivia, V., *see* Verma-Ansil, 946
Saibara, T., *see* Onishi, 349
Saito, S., *see* Nishiguchi, 29
Sakaeda, H., *see* Onishi, 349
Saldivia, V., *see* Kawasaki, 273
Salen, G., *see* Batta, 414
Salhanick, A. I., *see* Amatruda, 1024
Salzmann, J.-L., *see* Valla, 482
Sampliner, R. E. Correspondence: To the Editor—The liver disease of asymptomatic patients with elevated aminotransferases, 524
Saracco, G., Mazzella, G., Rosina, F., Cancellieri, C., Lattore, V., Raise, E., Rocca, G., Giorda, L., Verme, G., Gasbarrini, G., Barbara, L., Bonino, F., Rizzetto, M. and Roda, E. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy, 336
Sasaki, M., *see* Nakanuma, 174
Sasaki, Y., Hayashi, N., Morita, Y., Ito, T., Kasahara, A., Fusamoto, H., Sato, N., Tohyama, M. and Kamada, T. Cellular analysis of c-Ha-*ras* gene expression in rat liver after $CCl_4$ administration, 494
Sato, N., *see* Sasaki, 494
Scarlett, L., *see* O'Hare, 207
Schaasberg, W., *see* Lelie, 36
Schaller, H., *see* Galle, 459
Schellekens, H., *see* Czaja, 795
Schlicht, H.-J., *see* Galle, 459
Schmidt, E., *see* Peltenburg, 833
Schrumpf, E. HEPATOLOGY *Elsewhere*—Association of primary sclerosing cholangitis and celiac disease: Fact or fancy?, 1020
Schubert, T., *see* Valenzuela, 958
Schuppan, D., *see* Milani, 84
Schuppan, D., *see* Ruwart, 801
Schwarz, L., *see* Greim, 260
Schwarz, R. E., Iwatsuki, S., Herberman, R. B. and Whiteside, T. L. Lymphokine-activated killer cell activity in patients with primary and metastatic malignant liver tumors, 221
Shefer, S., *see* Batta, 414
Sherlock, S. HEPATOLOGY *Elsewhere*—Spiders and capillaries, 388
Sherman, M., *see* Cai, 855
Sherman, M., *see* Fang, 781
Shi, Z., *see* Cai, 855
Shimizu, M., *see* Tsutsumi, 437
Shimizu, Y., *see* Nishiguchi, 29
Shimizu, Y. K. and Purcell, R. H. Cytoplasmic antigen in hepatocytes of chimpanzees infected with non-A, non-B hepatitis virus or hepatitis delta virus: Relationship to interferon, 764
Shiomi, S., *see* Nishiguchi, 29
Shirabe, K., *see* Sonoda, 1003
Shoenfeld, Y., *see* Konikoff, 525
Shouval, D., *see* Ackerman, 203
Sieg, A., Stiehl, A., Heirwegh, K. P. M., Fevery, J., Raedsch, R. and Kommerell, B. Similarities in maximal biliary bilirubin output in the normal rat after administration of unconjugated bilirubin or bilirubin diglucuronide, 14
Siekevitz, M., *see* Banerjee, 1008
Simoni, P., *see* Aldini, 840
Smallwood, R. A., *see* Morgan, 893
Smirnov, V. N., *see* Babaev, 56
Smith, J., *see* Lamers, 72
Smith, N. D., *see* Corasanti, 8
Snyder, R. L., *see* Michalak, 44
Soeters, P. B., *see* van Berlo, 315
Sonoda, T., Shirabe, K., Takenaka, K., Kanematsu, T., Yasumori, K. and Sugimachi, K. Angiographically undetected small hepatocellular carcinoma: Clinicopathological characteristics, follow-up and treatment, 1003
Sorrell, M. F., *see* Lieber, 501
Starzl, T. E., *see* Kahn, 861
Stein, H., *see* Milani, 84
Stellon, A. J., *see* Polson, 279
Stemerowicz, R., *see* Möller, 179
Stewart, D. J. Monitoring of sodium:proton exchange in isolated hepatocytes by electronic cell sizing, 986
Stiehl, A., *see* Sieg, 14
Strong, R. M., *see* Valenzuela, 958
Suchy, F. J., *see* Novak, 447
Sugimachi, K., *see* Kanematsu, 98
Sugimachi, K., *see* Sonoda, 1003
Sun, A. M., *see* Cai, 855
Suou, T., Civeira, M. P., Kanof, M. E., Moreno-Otero, R., Jones, E. A. and James, S. P. Defective immunoregulation in primary biliary

cirrhosis: CD4+, Leu-8+ T cells have abnormal activation and suppressor function *in vitro*, 408
Surh, C. D., Roche, T. E., Danner, D. J., Ansari, A., Coppel, R. L., Prindiville, T., Dickson, E. R. and Gershwin, M. E. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex, 127
Suzuki, S., *see* Mitsui, 324

Takahashi, S., *see* Czaja, 795
Takahashi, T., *see* Orozco, 903
Takeda, T., *see* Nishiguchi, 29
Takenaka, K., *see* Kanematsu, 98
Takenaka, K., *see* Sonoda, 1003
Tanaka, Y., *see* Caldwell-Kenkel, 292
Taylor, C. R. HEPATOLOGY *Elsewhere*—Assessment of portal vein patency: Pitfalls and problems in diagnostic comparative studies, 117
Taylor, L. W., *see* Valenzuela, 958
Terada, T. and Nakanuma, Y. Survey of iron-accumulative macroregenerative nodules in cirrhotic livers, 851
Terés, J., *see* Bosch, 962
Terés, J. HEPATOLOGY *Elsewhere*— Balloon tamponade vs. endoscopic sclerotherapy in the management of active variceal hemorrhage, 393
Theodor, E., *see* Konikoff, 525
Thistlethwaite, J. R., *see* Emond, 867
Thomas, C. E. and Reed, D. J. Special Article—Current status of calcium in hepatocellular injury, 375
Thomas, H. C., *see* Brook, 761
Thurman, R. G., *see* Caldwell-Kenkel, 292
Tillery, G. W., *see* Klintmalm, 978
Tinel, M., *see* Larrey, 168
Tint, G. S., *see* Batta, 414
Tiribelli, C., Melato, M., Crocè, L. S., Giarelli, L., Okuda, K. and Ohnishi, K. Prevalence of hepatocellular carcinoma and relation to cirrhosis: Comparison of two different cities of the world—Trieste, Italy, and Chiba, Japan, 998
Tohyama, M., *see* Sasaki, 494
Tredger, J. M. and Williams, R. HEPATOLOGY *Elsewhere*—Drug-binding proteins after liver transplantation: Are they significant?, 390
Trepo, C., *see* Fourel, 186
Trepo, C., *see* Marcellin, 328
Tsai, Y.-T., Lee, F.-Y., Lin, H.-C., Chang, T.-T., Lay, C.-S., Wang, S.-S., Kong, C.-W., Lee, S.-D. and Lo, K.-J. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis, 283
Tsibulsky, V. P., *see* Babaev, 56
Tsuda, F., *see* Akahane, 398
Tsuda, F., *see* Mitsui, 324
Tsukamoto, H., *see* French, 898
Tsutsumi, M., Lasker, J. M., Shimizu, M., Rosman, A. S. and Lieber, C. S. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver, 437
Tsutsumi, Y., *see* Yoshioka, 769
Tulassay, T., Tulassay, Z. and Rascher, W. Correspondence: To the Editor—Are there any characteristic changes in the plasma concentration of atrial natriuretic factor in liver cirrhosis?, 263
Tulassay, Z., *see* Tulassay, 263

Urbain, D. and Ham, H. R. Correspondence: To the Editor—Thallium per rectum scintigraphy, portal pressure and portal perfusion, 262

Vakil, N., *see* Knyrim, 134
Valenzuela, J. E., Schubert, T., Fogel, M. R., Strong, R. M., Levine, J., Mills, P. R., Fabry, T. L., Taylor, L. W., Conn, H. O., Posillico, J. T. and a Multicenter Study Group. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices, 958
Valinluck, B., *see* Govindarajan, 34
Valla, D., Flejou, J.-F., Lebrec, D., Bernuau, J., Rueff, B., Salzmann, J.-L. and Benhamou, J.-P. Portal hypertension and ascites in acute hepatitis: Clinical, hemodynamic and histological correlations, 482
Valla, D., *see* Ramond, 488
van Amelsfoort, P. J. A. J., *see* Lelie, 36
van Berlo, C. L. H., van de Bogaard, A. E. J. M., van der Heijden, M. A. H., van Eijk, H. M. H., Janssen, M. A., Bost, M. C. F. and Soeters, P. B. Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of isoleucine in hemoglobin? A study in pigs, 315
van de Bogaard, A. E. J. M., *see* van Berlo, 315
van der Heijden, M. A. H., *see* van Berlo, 315
van der Meide, P. H., *see* Czaja, 795
van Eijk, H. M. H., *see* van Berlo, 315
Van Hattum, J., *see* Beutler, 148
van Noorden, C. J. F., *see* Lamers, 72
Van Thiel, D. H., *see* Kahn, 861
Varghese, G., *see* Verma-Ansil, 946
Varmus, H., *see* Chang, 332
Vaubourdolle, M., *see* Guéchot, 346
Verma-Ansil, B., Carmichael, F. J., Saldivia, V., Varghese, G. and Orrego, H. Effect of ethanol on splanchnic hemodynamics in awake and unrestrained rats with portal hypertension, 946
Verme, G., *see* Brunetto, 198
Verme, G., *see* Saracco, 336
Vidmar, T. J., *see* Ruwart, 801
Vincent, S. H., *see* Knobler, 995
Vincent, W. R., *see* Knobler, 995
Vonk, R. J., *see* Bijleveld, 1031
Voth, R., *see* Mayet, 24
Vyberg, M. Diverticular bile duct lesion in chronic active hepatitis, 774

Wallace, J. L., *see* Guarner, 788
Wang, K. K., Czaja, A. J., Beaver, S. J. and Go, V. L. W. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis, 39
Wang, S.-S., *see* Tsai, 283
Wanless, I. R. HEPATOLOGY *Elsewhere*—Coexistent pulmonary and portal hypertension: Yin and yang, 255
Warren, W. D., *see* Henderson, 288
Watanabe, K., *see* Fourel, 186
Watson, A. J., *see* Mitchison, 420
Wax, Y., *see* Ackerman, 203
Weimer, T., *see* Fuchs, 215
Weiner, F. R., *see* Czaja, 795
Wells, P. G., *see* de Morais, 163
Wernze, H., *see* Goerig, 154
Westaby, D., *see* Polson, 279
Whiteside, T. L., *see* Schwarz, 221
Whitington, P. F., *see* Emond, 867
Wiesner, R. H., Grambsch, P. M., Dickson, E. R., Ludwig, J., MacCarty, R. L., Hunter, E. B., Fleming, T. R., Fisher, L. D., Beaver, S. J. and LaRusso, N. F. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis, 430
Wilkinson, K. F., *see* Ruwart, 801
Willems, B., *see* Pomier-Layrargues, 969
Willems, G. M., *see* Peltenburg, 833
Williams, R., *see* Forbes, 306
Williams, R., *see* Polson, 279
Williams, R., *see* Tredger, 390

Williams, S. J. and Farrell, G. C. Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity, 192
Witte, C. L. and Witte, M. H. HEPATOLOGY *Elsewhere*—The portocardiorenal axis and refractory ascites: The underfilled cup runneth over, 114
Witte, M. H., *see* Witte, 114

Yamada, S., *see* Hasegawa, 973
Yamamoto, Y., *see* Onishi, 349
Yamazaki, C., *see* Mitsui, 324
Yamazaki, K. and LaRusso, N. F. Special Article—The liver and intracellular digestion: How liver cells eat!, 877
Yasumori, K., *see* Sonoda, 1003
Yeaman, S. J., *see* James, 247
Yeaman, S. J., *see* Mutimer, 403
Yoshida, Y., *see* Kanematsu, 98
Yoshioka, K., Kakumu, S., Arao, M., Tsutsumi, Y. and Inoue, M. Tumor necrosis factor $\alpha$ production by peripheral blood mononuclear cells of patients with chronic liver disease, 769

Zatloukal, K., *see* Denk, 514
Zeldis, J. B. HEPATOLOGY *Elsewhere*—Aplastic anemia after liver transplantation for fulminant viral hepatitis: Black box or bag of worms?, 520
Zeng, Q., *see* Kahn, 861
Zern, M. A., *see* Czaja, 795
Zielinski, C. C., *see* Müller, 928
Zignego, L., *see* Pol, 342
Zuckerman, A. J., *see* Panda, 466